Miltenyi, 130-133-128, StraightFrom® Whole Blood REAlease® CD19 MicroBead Kit, human

Detailed separation procedure
CD19+ cells are labelled with StraightFrom Whole Blood REAlease CD19-Biotin (REAlease Biotin Complex). Subsequently, StraightFrom Whole Blood REAlease Anti-Biotin MicroBeads (CD19, human) bind to REAlease Biotin Complex. Then, the cell suspension is loaded onto a MACS Column, which is placed in the magnetic field of a MidiMACS or QuadroMACS separator. Using the REAlease Bead Release Reagent, which removes the MicroBeads from the cell, target cells are eluted within the magnetic field. Finally, during the subsequent incubation with the REAlease Release Reagent, the REAlease Biotin Complex monomerizes and dissociates from the cell surface leaving the target cells free of all labels.

Downstream applications
StraightFrom Whole Blood REAlease CD19 MicroBead Kit allows the fast isolation of CD19+ cells directly from blood thus minimizing hands-on time and maximizing yields of target cells. The purified CD19+ cells are well-suited for further flow cytometric, functional, or molecular analysis. The isolated CD19+ cell subset is label-free.

Columns
Whole Blood columns, Multi-24 Whole Blood Column Block

Overview
StraightFrom Whole Blood REAlease CD19 MicroBead Kit was developed for rapid positive selection of CD19+ cells directly from whole blood. No sample preparation is required, including density gradient centrifugation or erythrocyte lysis.
The purified target cells are bead-free, practical for consecutive magnetic isolations, and are left label-free so that epitopes are available for any downstream application.